Synthesis and biological evaluation of some new pyrimidines via a novel chalcone series

Amit R. Trivedi, Dipti K. Dodiya, Naresh R. Ravat, and Viresh H. Shah*

Department of Chemistry, Saurashtra University, Rajkot (Gujarat), India, Pin-360005
E-mail: shahv_h@yahoo.com

Abstract
In the present investigation ethyl 2-(4-carboxyphenylazo)acetoacetate 1 on condensation with various aromatic aldehydes in ethanolic NaOH solution yielded the corresponding chalcones 2a-j. These chalcones were further reacted with urea in the presence of base in ethanol, which led to the formation of pyrimidine derivatives 3a-j. The newly synthesized heterocycles were characterized on the basis of their chemical properties and spectroscopic data. All newly synthesized compounds were evaluated for their antimycobacterial activities against Mycobacterium tuberculosis H37Rv.

Keywords: Pyrimidine, antimycobacterial, Mycobacterium tuberculosis

Introduction
Tuberculosis (TB) is by far the most frequently encountered mycobacterial disease in the world. Although its incidence has diminished significantly in the industrially more developed countries; it remains a major public health problem in most of the developing nations. Tuberculosis is still the single largest infection having a high mortality rate and 0.1 to 0.3 percent of the population become infected each year in the developed countries. This year, 2 million people may develop the disease and 30 million may die worldwide (as per a WHO report). It is commonly known that Mycobacterium tuberculosis has developed resistance to the majority of the existing drugs. However, powerful new anti-TB drugs with new mechanisms of action have not been developed in the last forty years. In the developing countries, the annual infection rate is 20–50 times greater than in the developed countries and its high level shows little or no downward trend. It is expected that development of new effective anti-TB drugs will bring various outcomes viz: shortening the total duration of therapy, reducing the total expenditure and treatment of multiple drug resistant tuberculosis (MDR-TB) by single dosage regiment. In pursuit of achieving this goal, our research efforts are focused on the development of novel structural moieties having antimycobacterial properties. Chalcones have various biological activities such as cytotoxic,
antimalarial,\textsuperscript{6} antioxidant,\textsuperscript{7} tyrosinase Inhibitory,\textsuperscript{8} anti-inflammatory,\textsuperscript{9} cancer chemopreventive\textsuperscript{9} and antibacterial.\textsuperscript{10} Several pyrimidine derivatives have wide varieties of usages and its nucleus is also present in vitamin B\textsubscript{2} and folic acid. Pyrimidine heterocycles possessing hydroxyl group has a unique place in medicinal chemistry,\textsuperscript{11} and also plays a vital role in biological processes\textsuperscript{12}, \textsuperscript{13} as well as synthetic drugs.\textsuperscript{14} Pyrimidines are associated with various therapeutic activities \textit{e.g.}, anti-HIV,\textsuperscript{15} anti-tubercular,\textsuperscript{16} antitumor,\textsuperscript{17} antineoplastic,\textsuperscript{18} anti-inflammatory,\textsuperscript{19} diuretic,\textsuperscript{20} antimalaria,\textsuperscript{21} cardiovascular.\textsuperscript{22} To the best of our knowledge, there has been no previous reports of analogous pyrimidines and parent chalcones as antituberculosis agents. However, there are numerous examples of nitrogen containing heterocycles being used to treat TB, for example Clofazimine, Isoniazid and Pyrazinamide. These compounds provide structural precedence that our chalcone and pyrimidine analogues may lead to the generation of novel anti-TB therapeutics. Herein the synthesis and \textit{in vitro} antimycobacterial activity of novel chalcone and pyrimidine derivatives are described.

\textbf{Results and Discussion}

\textbf{Chemistry}

The synthesis of chalcone and pyrimidine derivatives was performed following the steps shown in Scheme-1. In the initial step, chalcones (2a-j) were synthesized by condensing 2-(4-carboxyphenylazo)acetoacetate\textsuperscript{23} with appropriate aromatic aldehydes in dilute ethanolic sodium hydroxide solution at room temperature. The compounds (3a-j) were synthesized by reacting the appropriate chalcone with urea and potassium hydroxide in ethanol. The purity of the compounds was determined by TLC and elemental analysis. Spectral data (IR, \textsuperscript{1}H-NMR, \textsuperscript{13}C NMR and Mass) of all the newly synthesized compounds were in full agreement with the proposed structures.
Scheme 1

The possible mechanism involved in the formation of dihydropyrimidine derivatives (3a-j) from the respective chalcones (2a-j) is shown below.

R = Phenyl,
2-Hydroxyphenyl,
4- Hydroxyphenyl,
2-Nitrophenyl,
3- Nitrophenyl,
2-Chlorophenyl,
4-Methoxyphenyl,
3-Methoxy-4-hydroxy-phenyl,
Styryl,
2-Furyl,
Biological screening

Microbiology
The *in vitro* activities of the synthesized compounds (2a-j & 3a-j) for tuberculosis inhibition against the *Mycobacterium tuberculosis* H$_{37}$Rv (ATCC27294) strain were performed using the micro plate alamar blue assay (MABA) method at TAACF. Compounds exhibiting fluorescence are tested in a BACTEC-460 radiometric system and/or broth micro dilution assay. The activities are expressed as minimum inhibitory concentration (MIC, µg/mL) and are summarized in Table 1. Compounds demonstrating at least 90% inhibition were re-tested at lower concentrations to determine the actual MIC, a value defined as the lowest concentration inhibiting ≈ 90% of the inoculums relative to the control.

Antimycobacterial activity
Twenty compounds were screened for their antimycobacterial activity against *Mycobacterium tuberculosis* H$_{37}$Rv using a BACTEC-460 radiometric system. Among the chalcones 2a-j and pyrimidines 3a-j, compounds 3d, 3e and 3g produced the highest efficacy and exhibited >90% inhibition at 6.25 µg/ml in the primary screen (Table 1). Compounds 2a-j, 3a-c, 3f and 3h-j exhibited >90% inhibition against *Mycobacterium tuberculosis* at 6.25 µg/mL (Table 1). These antimycobacterial data clearly indicated that the presence of 2-nitro, 3-nitro and 4-methoxy substitution on chalcone produced remarkable improvements in antitubercular activity.
Table 1. *In vitro* antimycobacterial screening data of 2a-j & 3a-j

| Sr. No. | R Molecular Formula | MIC µg/mL | Inhibition |
|---------|---------------------|-----------|------------|
| 2a      | Phenyl C₁₇H₁₄N₂O₃  | <6.25     | -          |
| 2b      | 2-Hydroxyphenyl C₁₇H₁₄N₂O₄ | <6.25 | 10        |
| 2c      | 4- Hydroxyphenyl C₁₇H₁₄N₂O₄ | <6.25 | 20        |
| 2d      | 2-Nitrophenyl C₁₇H₁₃N₃O₅ | <6.25 | 56        |
| 2e      | 3- Nitrophenyl C₁₇H₁₃N₃O₅ | <6.25 | 50        |
| 2f      | 2-Chlorophenyl C₁₇H₁₃N₂O₃Cl  | <6.25 | 25        |
| 2g      | 4-Methoxyphenyl C₁₈H₁₆N₂O₄ | <6.25 | 28        |
| 2h      | 3-Methoxy-4-hydroxy-phenyl C₁₈H₁₆N₂O₅ | >6.25 | 38        |
| 2i      | Styryl C₁₉H₁₆N₂O₃  | >6.25     | 18        |
| 2j      | 2-Furyl C₁₃H₁₂N₂O₄  | <6.25     | -         |
| 3a      | Phenyl C₁₈H₁₆N₄O₃  | <6.25     | 90        |
| 3b      | 2-Hydroxyphenyl C₁₈H₁₆N₄O₄ | >6.25 | 92        |
| 3c      | 4- Hydroxyphenyl C₁₈H₁₆N₄O₄ | >6.25 | 87        |
| 3d      | 2-Nitrophenyl C₁₈H₁₅N₅O₅ | >6.25 | 96        |
| 3e      | 3- Nitrophenyl C₁₈H₁₅N₅O₅ | >6.25 | 96        |
| 3f      | 2-Chlorophenyl C₁₈H₁₅N₄O₃Cl  | >6.25 | 92        |
| 3g      | 4-Methoxyphenyl C₁₉H₁₈N₄O₄ | >6.25 | 97        |
| 3h      | 3-Methoxy-4-hydroxy-phenyl C₁₉H₁₈N₄O₅ | <6.25 | 90        |
| 3i      | Styryl C₂₀H₁₈N₄O₃  | <6.25     | 81        |
| 3j      | 2-Furyl C₁₆H₁₄N₄O₄  | <6.25     | 75        |

Conclusions

In conclusion, a new class of chalcone and pyrimidines derivatives were synthesized and evaluated as antitubercular agents. The newly synthesized heterocycles exhibited promising antitubercular activities against *Mycobacterium tuberculosis*. These results makes novel chalcone and pyrimidine derivatives interesting lead molecules for further synthetic and biological evaluation. It can be concluded that this class of compounds certainly holds great promise towards the pursuit to discover novel classes of antimycobacterial agents. Further studies to acquire more information concerning structure–activity relationships are in progress.

Experimental Section

*General Procedures.* Chemicals were supplied by E. Merck (Germany) and S. D. Fine Chemicals (India). Melting points were determined by the open tube capillary method and are
uncorrected. The purity of the compounds was monitored by thin layer chromatography (TLC) plates (silica gel G) in the solvent system toluene–ethyl formate–formic acid (5:4:1) and benzene–methanol (8:2). The spots were observed by exposure to iodine vapours or by UV light. The IR spectra were obtained on a Perkin-Elmer 1720 FT-IR spectrometer (KBr pellets). The ¹H-NMR spectra were recorded on a Bruker AC 300 MHz spectrometer using TMS as the internal standard in DMSO-$_d_6$/CDCl$_3$. ¹³C-NMR (75 and 125 MHz) spectra were measured on a Bruker AC 200, DPX 300 and ARX 500, at 25 ºC, in CDCl$_3$. Elemental analyses of the newly synthesized compounds were carried out on Carlo Erba 1108 analyzer.

**General procedure for the synthesis of 3-(4'-aryl)-1-[(4)-carboxyphenylazomet hyl]-2-propene-1-one (2a-j)**

To a mixture of ethyl 2-(4-carboxyphenylazo)acetoacetate (1) (0.01 mol) and the appropriate aldehyde (0.01 mol) in oxygen-free ethanol was added a solution of sodium hydroxide in oxygen-free distilled water with constant stirring of the reaction flask. The reaction mixture was stirred for 24 hours on a magnetic stirrer and poured on to crushed ice. The solid mass that separated out was filtered, washed with water and crystallized from ethanol to furnish the desired product (2a-j) as yellow crystals.

**3-(4'-Phenyl)-1-[(4)-carboxyphenylazomethyl]-2-propene-1-one (2a).**

Yield 69%, mp. 156-158 ºC, IR (KBr): 1480 (N=N), 1682 (C=O), 1713 (C=O of acid), 3035–3042 (CH); ¹H-NMR (DMSO-$_d_6$): δ 3.00 (s, 2H, CH$_2$), 6.67 (d, 1H, H$_a$), 6.98 (d, 1H, H$_b$), 7.14–8.10 (m, 9H, aromatic), 11.00 (s, 1H, OH); ¹³C-NMR (CDCl$_3$): δ 58.2, 123.4, 126.5, 126.8, 127.9, 128.2, 128.9, 130.9, 136.2, 143.2, 157.2, 170.2, 197.5. Mass (m/z): 284. Anal. (%) for C$_{15}$H$_{12}$N$_2$O$_4$, Calcd. C, 63.38; H, 4.25; N, 9.85; O, 22.51; Found: C, 63.27; H, 4.12; N, 9.75; O, 22.40.

**3-(2'-Hydroxyphenyl)-1-[(4)-carboxyphenylazomethyl]-2-propene-1-one (2b).**

Yield 74%, mp. 196-198 ºC, IR (KBr): 1483 (N=N), 1676 (C=O), 1707 (C=O of acid), 3035–3042 (CH), 3253 (OH); ¹H–NMR (DMSO-$_d_6$): δ 3.03 (s, 2H, CH$_2$), 10.16 (s, 1H, Ar-OH), 6.35 (d, 1H, H$_a$), 6.93 (d, 1H, H$_b$), 7.18–8.10 (m, 8H, aromatic), 11.03 (s, 1H, OH); ¹³C-NMR (CDCl$_3$): δ 58.7, 115.9, 116.8, 122.3, 122.9, 126.7, 127.9, 128.1, 130.2, 131.1, 143.4, 156.7, 158.9, 170.1, 197.2. Mass (m/z): 310. Anal. (%) for C$_{17}$H$_{14}$N$_2$O$_4$, Calcd. C, 65.80; H, 4.55; N, 9.03; O, 20.62; Found: C, 65.69; H, 4.43; N, 8.91; O, 20.50.

**3-(4'-Hydroxyphenyl)-1-[(4)-carboxyphenylazomethyl]-2-propene-1-one (2c).**

Yield 70%, mp. 170-172 ºC, IR (KBr): 1484 (N=N), 1689 (C=O), 1705 (C=O of acid), 3039 (CH), 3353 (OH); ¹H–NMR (DMSO-$_d_6$): δ 3.10 (s, 2H, CH$_2$), 5.10 (s, 1H, Ar-OH), 6.44 (d, 1H, H$_a$), 6.93 (d, 1H, H$_b$), 7.08–7.54 (m, 8H, aromatic), 11.03 (s, 1H, OH); ¹³C-NMR (CDCl$_3$): δ 58.3, 116.2, 122.9, 126.6, 127.5, 128.1, 131.1, 143.4, 156.7, 157.9, 170.3, 198.1. Mass (m/z): 310. Anal. (%) for C$_{17}$H$_{14}$N$_2$O$_4$, Calcd. C, 65.80; H, 4.55; N, 9.03; O, 20.62; Found: C, 65.67; H, 4.41; N, 8.92; O, 20.52.

**3-(2'-Nitrophenyl)-1-[(4)-carboxyphenylazomethyl]-2-propene-1-one (2d).**

Yield 72%, mp. 181-183 ºC, IR (KBr): 1365 (NO$_2$), 1489 (N=N), 1692 (C=O), 1713 (C=O of acid), 3039 (CH); ¹H–NMR (DMSO-$_d_6$): δ 3.10 (s, 2H, CH$_2$), 6.78 (d, 1H, H$_a$), 7.14 (d, 1H, H$_b$), 7.40–8.10 (m, 8H,
aromatic), 11.20 (s, 1H, OH); 13C-NMR (CDCl₃): δ 58.2, 121.4, 122.7, 126.6, 127.8, 129.1, 130.4, 131.1, 135.1, 143.2, 146.8, 156.9, 170.8, 197.8. Mass (m/z): 339. Anal. (%) for C₁₇H₁₃N₃O₅, Calcd. C, 60.18; H, 3.86; N, 12.38; O, 23.58; Found: C, 60.07; H, 3.73; N, 12.26; O, 23.46.

3-(3'-Nitrophenyl)-1-[(4)-carboxyphenylazomethyl]-2-propene-1-one (2e). Yield 68%, mp. 197-199 ºC, IR (KBr) 1363 (NO₂), 1485 (N=N), 1680 (C=O), 1703 (C=O of acid), 3042 (CH); ¹H–NMR (DMSO-d6): δ 3.0 (s, 2H, CH₂), 6.84 (d, 1H, Hα), 7.18 (d, 1H, Hβ), 7.32–8.10 (m, aromatic), 11.10 (s, 1H, OH); 13C-NMR (CDCl₃): δ 58.6, 120.8, 121.9, 122.9, 126.8, 127.5, 130.3, 131.1, 132.9, 143.5, 149.2, 157.2, 170.6, 196.9. Mass (m/z): 310. Anal. (%) for C₁₇H₁₄N₂O₄, C, 65.80; H, 4.55; N, 9.03; O, 20.62; Found: C, 65.67; H, 4.43; N, 8.89; O, 20.51.

3-(2'-Chlorophenyl)-1-[(4)-carboxyphenylazomethyl]-2-propene-1-one (2f). Yield 71%, mp. 200-202 ºC, IR (KBr): 760 (Cl), 1481 (N=N), 1689 (C=O), 1715 (C=O of acid), 3043 (CH); ¹H–NMR (DMSO-d6): δ 3.12 (s, 2H, CH₂), 6.47 (d, 1H, Hα), 6.87 (d, 1H, Hβ), 7.08–8.10 (m, aromatic), 11.03 (s, 1H, OH); 13C-NMR (CDCl₃): δ 58.0, 123.0, 124.9, 126.7, 126.9, 127.8, 130.6, 131.1, 135.2, 137.2, 143.5, 157.4, 171.1, 197.9. Mass (m/z): 328. Anal. (%) for C₁₇H₁₃ClN₂O₃, C, 62.11; H, 3.99; Cl, 10.78; N, 8.52; O, 14.60; Found: C, 62.00; H, 3.86; Cl, 10.63; N, 8.41; O, 14.46.

3-(4'-Methoxyphenyl)-1-[(4)-carboxyphenylazomethyl]-2-propene-1-one (2g). Yield 70%, mp. 203-205 ºC, IR (KBr): 1159 (C-O-C), 1488 (N=N), 1682 (C=O), 1707 (C=O of acid), 3042 (CH); ¹H–NMR (DMSO-d6): δ 3.10 (s, 1H, -OCH₃), 6.37 (d, 1H, Hα), 6.89 (d, 1H, Hβ), 6.92–8.10 (m, aromatic), 11.13 (s, 1H, OH) 13C-NMR (CDCl₃): δ 55.5, 58.4, 114.8, 122.9, 127.4, 127.6, 127.8, 131.1, 143.1, 156.8, 160.3, 169.8, 197.2. Mass (m/z): 324. Anal. (%) for C₁₈H₁₆N₂O₄, Calcd. C, 66.66; H, 4.97; N, 8.64; O, 19.73; Found: C, 66.55; H, 4.86; N, 8.52; O, 19.61.

3-(3-Methoxy-4-hydroxy-phenyl)-1-[(4)-carboxyphenylazomethyl]-2-propene-1-one (2h). Yield 66%, mp. 180-182 ºC, IR (KBr): 1153 (C-O-C), 1485 (N=N), 1716 (C=O of acid), 3039 (CH); ¹H–NMR (DMSO-d6): δ 3.10 (s, 2H, CH₂), 3.73 (s, 1H, OCH₃), 6.34 (d, 1H, Hα), 6.78 (d, 1H, Hβ), 6.92–8.10 (m, aromatic), 11.13 (s, 1H, -OH) 13C-NMR (CDCl₃): δ 56.2, 58.4, 112.9, 116.7, 120.4, 122.9, 126.6, 127.8, 131.9, 143.5, 152.5, 157.4, 171.1, 197.3. Mass (m/z): 370. Anal. (%) for C₁₈H₁₆N₂O₅, Calcd. C, 63.52; H, 4.74; N, 8.23; O, 23.51; Found: C, 63.40; H, 4.61; N, 8.11; O, 23.38.

3-(Styryl)-1-[(4)-carboxyphenylazomethyl]-2-propene-1-one (2i). Yield 64%, mp. 207-209 ºC, IR (KBr): 1484 (N=N), 1690 (C=O), 1718 (C=O of acid), 3038 (CH); ¹H–NMR (DMSO-d₆): δ 3.12 (s, 2H, CH₂), 6.57 (d, 1H, Hα), 7.01 (d, 1H, Hβ), 7.14–8.10 (m, aromatic), 11.03 (s, 1H, OH); ¹³C-NMR (CDCl₃): δ 64.4, 122.6, 125.8, 126.7, 127.6, 128.2, 129.1, 130.5, 131.1, 131.8, 136.1, 142.8, 156.9, 170.6, 196.9. Mass (m/z): 320. Anal. (%) for C₁₉H₁₆N₂O₃, Calcd. C, 71.24; H, 5.03; N, 8.74; O, 14.98; Found: C, 71.12; H, 4.89; N, 8.61; O, 14.88.

3-(2-Furyl)-1-[(4)-carboxyphenylazomethyl]-2-propene-1-one (2j). Yield 66%, mp. 183-185 ºC, IR (KBr): 1155 (C-O-C), 1486 (N=N), 1687 (C=O), 1707 (C=O of acid), 3044 (CH); ¹H–NMR (DMSO-d₆): δ 3.12 (s, 2H, CH₂), 6.67–7.54 (dd, 1H, -CH=CH), 6.65–8.10 (m, 7H,
General method for the synthesis of 6-(4'-aryl)-4[(4)-carboxyphenylazomethyl]-2-hydroxyl-1,6-dihydropyrimidine (3a-j)

A mixture of 0.01 mol of the required chalcone (2a-j), 0.01 mol urea and KOH (1gm) in 20 ml ethanol was heated under reflux for 6 hours, then cooled and poured onto crushed ice. The so-obtained solid product was filtered and recrystalized from ethanol.

6-(4'-Phenyl)-4[(4)-carboxyphenylazomethyl]-2-hydroxyl-1,6-dihydropyrimidine (3a). Yield 63%, mp. 235-237 °C, IR (KBr): 1570 (C=C ring skeleton Ar moiety), 1415 (C=C ring skeleton pyrimidine moiety), 1480 (N=N), 1690 (C=O of acid), 3401 (OH); $^1$H–NMR (DMSO-d$_6$): $\delta$ 2.44 (s, 2H, CH$_2$), 4.49 (s, 1H, NH-CH), 4.90 (s, 1H, OH), 5.97 (d, 1H, CH), 6.61-7.96 (m, 9H, Ar-H), 12.32 (s, 1H, OH); $^{13}$C-NMR (CDCl$_3$): $\delta$ 47.2, 62.2, 118.2, 122.9, 127.1, 127.3, 128.8, 131.1, 139.6, 144.1, 156.7, 163.4, 170.1. Mass (m/z): 336. Anal. (%) for C$_{18}$H$_{16}$N$_4$O$_3$, Calcul. C, 64.28; H, 4.79; N, 16.66; O, 14.27. Found: C, 64.28; H, 4.79; N, 16.66; O, 14.27.

6-(2'-Hydroxyphenyl)-4[(4)-carboxyphenylazomethyl]-2-hydroxyl-1,6-dihydropyrimidine (3c).

Yield 72%, mp. 249-251 °C, IR (KBr): 1556 (C=C ring skeleton Ar moiety), 1418 (C=C ring skeleton pyrimidine moiety), 1479 (N=N), 1692 (C=O of acid), 3412 (OH); $^1$H–NMR (DMSO-d$_6$): $\delta$ 2.47 (s, 2H, CH$_2$), 4.46 (d, 1H, NH-CH), 4.86 (s, 1H, OH), 5.24 (s, 1H, NH), 5.90 (d, 1H, CH), 6.60-7.96 (m, 8H, Ar-H), 11.88 (s, 1H, OH), 12.29 (s, 1H, OH$_{acid}$); $^{13}$C-NMR (CDCl$_3$): $\delta$ 47.2, 62.6, 115.9, 117.9, 121.6, 127.9, 128.3, 128.9, 131.3, 139.9, 154.7, 163.6, 171.1. Mass (m/z): 352. Anal. (%) for C$_{18}$H$_{16}$N$_4$O$_4$, Calcul. C, 61.36; H, 4.58; N, 15.90; O, 18.16. Found: C, 61.36; H, 4.58; N, 15.90; O, 18.16.

6-(4'-Nitrophenyl)-4[(4)-carboxyphenylazomethyl]-2-hydroxyl-1,6-dihydropyrimidine (3d).

Yield 76%, mp. 227-229 °C, IR (KBr): 1563 (C=C ring skeleton Ar moiety), 1380 (NO$_2$), 1412 (C=C ring skeleton pyrimidine moiety), 1483 (N=N), 1698 (C=O of acid), 3402 (OH); $^1$H–NMR (DMSO-d$_6$): $\delta$ 2.42 (s, 2H, CH$_2$), 4.47 (d, 1H, NH-CH), 4.80 (s, 1H, OH), 5.26 (s, 1H, NH), 5.91 (d, 1H, CH), 7.11-8.92 (m, 8H, Ar-H), 12.19 (s, 1H, OH); $^{13}$C-NMR (CDCl$_3$): $\delta$ 38.4, 63.6, 118.4, 121.4, 122.8, 127.4, 127.9, 131.2, 134.6, 138.3, 139.4, 148.1, 156.9, 163.9, 172.1. Mass (m/z): 381. Anal. (%) for C$_{18}$H$_{15}$N$_5$O$_5$, Calcul. C, 56.69; H, 3.96; N, 18.37; O, 20.98; Found: C, 56.69; H, 3.96; N, 18.37; O, 20.98.
6-(3'-Nitrophenyl)-4[(4)-carboxyphenylazomethyl]-2-hydroxyl-1,6-dihydropyrimidine (3e). Yield 68%, mp. 279-281 °C, IR (KBr): 1565 (C=C ring skeleton Ar. moiety), 1378 (NO2), 1411 (C=C ring skeleton pyrimidine moiety), 1478 (N=N), 1694 (C=O of acid), 3212 (N-H), 3412 (OH); 1H–NMR (DMSO-d6): δ 2.39 (s, 2H, CH2), 4.46 (d, 1H, NH-CH), 4.79 (s, 1H, OH), 5.21 (s, 1H, NH), 5.90 (d, 1H, CH), 7.08-8.42 (m, 8H, Ar-H), 12.21 (s, 1H, OH); 13C-NMR (CDCl3): δ 46.2, 62.8, 118.2, 119.3, 122.6, 122.9, 128.2, 130.2, 131.6, 133.0, 139.9, 144.9, 149.2, 156.8, 164.2, 169.8. Mass (m/z): 381. Anal. (%) for C18H15N5O5, Calcd. C, 56.69; H, 3.96; N, 18.37; O, 20.98.

6-(2'-Chlorophenyl)-4[(4)-carboxyphenylazomethyl]-2-hydroxyl-1,6-dihydropyrimidine (3f). Yield 65%, mp. 251-253 °C, IR (KBr): 756 (Cl), 1561 (C=C ring skeleton Ar. moiety), 1415 (C=C ring skeleton pyrimidine moiety), 1487 (N=N), 1696 (C=O of acid), 3208 (N-H), 3412 (OH); 1H–NMR (DMSO-d6): δ 2.44 (s, 2H, CH2), 4.49 (d, 1H, NH-CH), 4.90 (s, 1H, OH), 5.24 (s, 1H, NH), 5.94 (d, 1H, CH), 7.11-8.36 (m, 8H, Ar-H), 12.29 (s, 1H, OH); 13C-NMR (CDCl3): δ 37.9, 62.1, 118.1, 123.1, 126.9, 127.6, 128.3, 128.6, 128.9, 131.4, 132.7, 139.4, 143.4, 156.9, 163.6, 170.6. Mass (m/z): 370. Anal. (%) for C18H15ClN4O3, Calcd. C, 58.31; H, 4.08; Cl, 9.56; N, 15.11; O, 12.94.

6-(4'-Methoxyphenyl)-4[(4)-carboxyphenylazomethyl]-2-hydroxyl-1,6-dihydropyrimidine (3g). Yield 73%, mp. 219-221 °C, IR (KBr): 1560 (C=C ring skeleton Ar. moiety), 1415 (C=C ring skeleton pyrimidine moiety), 1487 (N=N), 1693 (C=O of acid), 3210 (N-H), 3400 (OH); 1H–NMR (DMSO-d6): δ 2.34 (s, 2H, CH2), 3.72 (s, 1H, OCH3), 4.46 (d, 1H, NH-CH), 4.85 (s, 1H, OH), 5.19 (s, 1H, NH), 5.92 (d, 1H, CH), 6.42-8.06 (m, 8H, Ar-H), 12.32 (s, 1H, OH); 13C-NMR (CDCl3): δ 46.9, 56.4, 62.3, 114.9, 117.9, 121.4, 127.6, 128.7, 131.4, 136.3, 140.3, 156.4, 159.2, 163.9, 169.8. Mass (m/z): 366. Anal. (%) for C19H18N4O4, Calcd. C, 62.29; H, 4.95; N, 15.29; O, 17.47. Found: C, 62.29; H, 4.95; N, 15.29; O, 17.47.

6-(3-Methoxy-4-hydroxy-phenyl)-4[(4)-carboxyphenylazomethyl]-2-hydroxyl-1,6-dihydropyrimidine (3h). Yield 75%, mp. 241-243 °C, IR (KBr): 1559 (C=C ring skeleton Ar. moiety), 1411 (C=C ring skeleton pyrimidine moiety), 1487 (N=N), 1693 (C=O of acid), 3210 (N-H), 3400 (OH); 1H–NMR (DMSO-d6): δ 2.49 (s, 2H, CH2), 3.69 (s, 1H, OCH3), 4.47 (d, 1H, NH-CH), 4.81 (s, 1H, OH), 5.14 (s, 1H, NH), 5.95 (d, 1H, CH), 6.59-7.96 (m, 7H, Ar-H), 11.84 (s, 1H, OH), 12.39 (s, 1H, OH); 13C-NMR (CDCl3): δ 47.5, 56.9, 62.3, 114.9, 117.9, 122.8, 127.6, 128.7, 131.4, 136.3, 140.3, 156.4, 159.2, 163.9, 169.8. Mass (m/z): 382. Anal. (%) for C19H18N4O5, Calcd. C, 59.68; H, 4.95; N, 15.29; O, 20.92.

6-(Styryl)-4[(4)-carboxyphenylazomethyl]-2-hydroxyl-1,6-dihydropyrimidine (3i). Yield 66%, mp. 244-246 °C, IR (KBr): 1554 (C=C ring skeleton Ar. moiety), 1423 (C=C ring skeleton pyrimidine moiety), 1486 (N=N), 1699 (C=O of acid), 3411 (OH); 1H–NMR (DMSO-d6): δ 2.48 (s, 2H, CH2), 4.18 (d, 1H, NH-CH), 4.79 (s, 1H, OH), 5.21 (s, 1H, NH), 6.12 (d, 1H, CH), 6.29 (dd, 1H, CH), 6.64 (d, 2H, CH), 7.14-8.31 (m, 8H, Ar-H), 12.40 (s, 1H, OH); 13C-NMR (CDCl3): δ 49.6, 62.7, 118.2, 123.1, 123.7, 126.7, 127.8, 128.2, 128.9, 129.7, 131.2, 140.0, 157.4, 163.5.
170.7. Mass (m/z): 362. Anal. (%) for C_{20}H_{18}N_{4}O_{3}, Calcd. C, 66.29; H, 5.01; N, 15.46; O, 13.25; Found: C, 66.29; H, 5.01; N, 15.46; O, 13.25.

6-(2-Furyl)-4[(4)-carboxyphenylazomethyl]-2-hydroxyl-1,6-dihydropyrimidine (3j). Yield 64%, mp. 236-238 ºC, IR (KBr) 1569 (C=C ring skeleton Ar . moiety), 1418 (C=C ring skeleton pyrimidine moiety), 1489 (N=N), 1701 (C =O of acid), 3210 (N-H), 3404 (OH); 1H–NMR (DMSO-\textit{d}_6): δ 2.39 (s, 2H, CH\textsubscript{2}), 4.49 (d, 1H, NH-CH\textsubscript{2}), 4.84 (s, 1H, OH), 5.14 (s, 1H, NH), 5.89 (d, 1H, CH), 6.32-8.29 (m, 7H, Ar-H, furyl), 12.30 (s, 1H, OH); 13C-NMR (CDCl\textsubscript{3}): δ 48.2, 62.3, 107.3, 111.3, 118.6, 122.7, 127.6, 131.2, 139.8, 142.0, 153.6, 157.4, 163.7, 171.6. Mass (m/z): 326. Anal. (%) for C\textsubscript{16}H\textsubscript{14}N\textsubscript{4}O\textsubscript{4}, Calcd. C, 58.89; H, 4.32; N, 17.17; O, 19.61; Found: C, 58.89; H, 4.32; N, 17.17; O, 19.61.

Acknowledgements

The authors wish to thank the Professor and Head, Department of Chemistry Saurashtra University, Rajkot for research facilities. Authors are thankful to CDRI Lucknow for spectral and analytical data. We thank the Tuberculosis Antimicrobial Acquisition and Coordinating Faculty (TAACF), www.taacf.org for the in vitro antimycobacterial screening.

References

1. http://www.who.int/tdr/diseases/tb/default.htm.
2. Dhar, D. N. The Chemistry of Chalcones and Related Compounds, Wiley: New York, 1981; p 5.
3. Raut, K. B.; Wendor, D. H. J. Org. Chem. 1960, 25, 2126.
4. Ariyan, Z. S.; Suschitzky, H. J. J. Chem. Soc. 1961, 2242.
5. Jurasek, A.; Knoppava, V.; Dandarova, M.; Kovac, A.; Reinprecht, J. Tetrahedron 1978, 34, 1883.
6. Subbraju, G. V.; RangaNayakulu, A.; Parameshwara, D. Indian J. Heterocyclic Chem. 1994, 4, 87.
7. Bhat, B. A.; Dhar, K. L.; Puri, S. C.; Saxena, A. K.; Shanmugavel, M.; Qazi, G. N. Bioorg. Med. Chem. Lett. 2005, 15, 3177.
8. Domínguez, J. N.; Rodrigues, C. J.; Gamboa de Domínguez, N.; Gut, J.; Philip, J.; Rosenthal, P. J. Farmaco 2005, 60, 307.
9. Yauli, N.; Üçüncü, O.; Aydin, E.; Gök, Y.; Yaar, A.; Baltaci, C.; Yildirim, N.; Küçük, M. J. Photochem. Photobiol. A: Chem. 2005, 169, 229.
10. Khatib, S.; Narya, O.; Musa, R.; Shmuel, M.; Tamir, S.; Vaya, J. Bioorg. Med. Chem. 2005, 13, 433.
11. Nigam, S. C.; Saharia, G. S.; Sharma, H. R. Indian Chem. Soc. 1983, 60, 583
12. Baddiley, J.; Lythgoe, B.; Todd, A. R. J. Chem. Soc. 1944, 318.
13. Kenner, G. W.; Lythgoe, B.; Todd, A. R. J. Chem. Soc. 1944, 652.
14. Centolella, A.P.; Nelson, J. W.; Kolloff, H. G. J. Am. Chem. Soc. 1943, 65, 209.
15. Noriyuki, K.; Hitoshi, M.; Shionogi & Co. Ltd., Japan PCT Int. Appl. WO 03, 47, 564, 2002; Chem. Abstr. 2003, 139, 36532c.
16. Jani, M. K.; Shah, B. R.; Undavia, N. K.; Trivedi, P. B. Chem. Abstr. 1994, 121, 35513p.
17. Safonova, T.V.; Keremov, A.F.; Ershova, Yu. A. Khim. Farm. Zn. 1998, 32 (12), 11, (Eng); Chem. Abstr. 1999, 131, 18975e.
18. Jean-Damien, C.; David, B.; Ronald, K.; Julian, G.; Pan, Li; Robert, D.; Vertex Pharmaceuticals Incorporated, USA; PCT Int. Appl. WO 02 22, 608, 2002; Chem. Abstr. 2002, 136, 247584x.
19. Nakaguti, O.; Shimazaki, N.; Shimazaki, M.; Nakatuka, M., Eur. Pat. Appl., 168, 005, 1986; Chem. Abstr. 1986, 105, 191118p.
20. Papesh, V.; Schroeder, E. F. US. Pat 2714559, 1956: Chem. Abstr. 1956, 50, 11370.
21. Tokutake, N.; Brit. Pat.146836B, 1977; Chem. Abstr. 1977, 87, 102370.
22. Kurono M.; JP, 62, 267, 272, 1987; Chem. Abstr. 1988, 109, 37382t.
23. Ojha, A. C.; Jain, R. Polish J. Chem. 1982, 56, 1553.
24. Franzblau, S. G.; Witzig, R. S.; McLaughlin, J. C.; Torres, P.; Madico, G.; Hernandez, A.; Degnan, M. T.; Cook, M. B.; Quenzer, V. K.; Ferguson, R. M.; Gilman, R. H. J. Clin. Microbiol. 1998, 36, 362.
25. Vanitha, J. D.; Paramasivan, C. N. Mycobacteriology 2004, 49, 179.
26. Reis, R. S.; Neves, I. S.; Lourenco, L. S.; Fonseca, L. S.; Lourenco, M. C. S. J. Clin. Microbiol. 2004, 42, 2247.